```html

Zollinger‑Ellison‑Related Peptic Ulcer Disease

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to produce very high amounts of acid, leading to recurrent peptic ulcers that are often multiple, large, and located beyond the duodenum.<sup>1</sup>

Although ZES accounts for less than 1 % of all peptic ulcer disease (PUD), the ulcers it causes are more aggressive and can be refractory to standard ulcer therapy. The condition can affect anyone, but it is most commonly diagnosed in adults between the ages of 30 and 60, with a slight male predominance.

Estimated prevalence is approximately 1–3 cases per million people worldwide, and because the tumors are usually slow‑growing, many patients are diagnosed only after years of unexplained ulcer symptoms.<sup>2</sup>

Symptoms

Symptoms arise from two main mechanisms: hyperacidic gastritis/ulceration and the mass effect of the gastrinoma.

• Recurrent abdominal pain – burning or gnawing pain that may improve with food (duodenal ulcers) or worsen after meals (gastric ulcers).
• Heartburn & gastro‑esophageal reflux disease (GERD) – due to excessive acid.
• Diarrhea or steatorrhea – acid inactivates pancreatic enzymes, leading to malabsorption.
• Nausea & vomiting – occasional; may contain blood if an ulcer is bleeding.
• Weight loss – from chronic pain, malabsorption, or tumor‑related cachexia.
• Gastrointestinal bleeding – melena or hematemesis, indicating an ulcer has eroded a blood vessel.
• Upper abdominal tenderness on physical exam.
• Signs of a pancreatic or duodenal mass – a palpable lump, jaundice (if tumor compresses the bile duct), or back pain.

Because ulcers can occur in atypical locations (jejunum, ileum), some patients experience vague, diffuse abdominal discomfort that is often misattributed to irritable bowel syndrome or functional dyspepsia.

Causes and Risk Factors

Primary cause

Zollinger‑Ellison syndrome is caused by gastrinomas, neuroendocrine tumors that secrete gastrin independent of normal regulatory mechanisms. About 25–30 % of gastrinomas arise in the context of Multiple Endocrine Neoplasia type 1 (MEN‑1)—a hereditary syndrome that also predisposes to pituitary and parathyroid tumors.<sup>3</sup>

Risk factors

• Family history of MEN‑1 or other neuroendocrine tumor syndromes.
• Age 30–60 (most cases diagnosed in this window).
• Male gender – a modestly higher incidence.
• Chronic use of proton‑pump inhibitors (PPIs) does NOT cause ZES, but may mask symptoms and delay diagnosis.

Diagnosis

Diagnosing ZES requires confirming hypergastrinemia, ruling out other causes of high gastrin, and locating the tumor.

Step‑wise diagnostic approach

1. Fasting serum gastrin level – Levels > 1,000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when accompanied by gastric pH < 2.
2. Secretin stimulation test – In ZES, gastrin paradoxically rises after intravenous secretin; a rise > 120 pg/mL is diagnostic.<sup>4</sup>
3. Upper endoscopy (EGD) – Visualizes ulcer size, number, and location; biopsies are taken to exclude malignancy.
4. Imaging for tumor localization:
   • CT or MRI abdomen – detects larger tumors (> 1 cm).
   • Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – most sensitive for small neuroendocrine tumors.
5. Endoscopic ultrasound (EUS) – High‑resolution tool for detecting pancreaticoduodenal lesions ≤ 5 mm.
6. Genetic testing – Recommended for patients with a family history of MEN‑1 or multiple endocrine tumors.

Treatment Options

Management aims to control gastric acid hypersecretion, eradicate ulcer disease, and treat or remove the gastrinoma.

Acid‑suppression therapy (first line)

• Proton‑pump inhibitors (PPIs) – High‑dose regimens (e.g., omeprazole 60 mg‑80 mg daily or equivalent) are required to maintain gastric pH > 4.<sup>5</sup>
• H2‑receptor antagonists may be added if PPIs alone are insufficient.
• Therapy is usually lifelong unless the gastrinoma is cured.

Surgical management

• Curative resection – Preferred for isolated, resectable tumors (especially < 2 cm). Enucleation or pancreaticoduodenectomy (Whipple procedure) may be performed.
• Debulking surgery – Reduces tumor burden and gastrin output when complete removal is impossible.
• Outcomes: ~70 % of patients achieve cure after successful resection; recurrence can occur, requiring ongoing surveillance.

Medical therapy for unresectable or metastatic disease

• Somatostatin analogues (octreotide, lanreotide) – Inhibit gastrin release and may shrink tumors.
• Targeted therapies – Everolimus or sunitinib (used for advanced pancreatic neuroendocrine tumors).
• Chemotherapy – Generally reserved for high‑grade or rapidly progressive disease.

Lifestyle and supportive measures

• Avoid NSAIDs, aspirin, and other ulcer‑aggravating drugs.
• Limit alcohol and caffeine, which can increase acid secretion.
• Small, frequent meals may reduce symptom burden.
• Maintain adequate calcium and vitamin D; chronic acid suppression can impair absorption.

Living with Zollinger‑Ellison‑related Peptic Ulcer Disease

Daily management tips

• Medication adherence – Take PPIs exactly as prescribed; missing doses can precipitate ulcer flare‑ups.
• Regular monitoring – Serum gastrin and gastric pH should be checked every 6–12 months; imaging every 1–2 years for tumor surveillance.
• Nutrition – Emphasize a balanced diet rich in lean protein, whole grains, and low‑fat dairy; consider a dietitian if malabsorption persists.
• Hydration – Diarrhea can lead to electrolyte loss; replace fluids with oral rehydration solutions if needed.
• Stress management – Chronic pain and medication burden can affect mental health; mindfulness, yoga, or counseling may be helpful.
• Vaccinations – Patients on long‑term PPIs have a modestly increased risk of C. diffident infection; keep up‑to‑date with influenza and COVID‑19 vaccines.

Follow‑up schedule

Visit Type	Frequency	Key Assessments
Gastroenterology	Every 6 months	Symptoms, PPI dosage, gastrin level
Endocrinology (if MEN‑1)	Annually	Calcium, parathyroid function, pituitary hormones
Imaging (CT/MRI or PET)	Every 12–24 months	Tumor size, new lesions

Prevention

Because ZES is driven by tumor biology, primary prevention is limited. However, the following measures can reduce ulcer‑related complications:

• Never use over‑the‑counter NSAIDs or aspirin without gastro‑protective co‑therapy.
• Limit alcohol intake (< 2 drinks/day for men, < 1 drink/day for women).
• Quit smoking – smoking impairs ulcer healing and raises gastrin levels.
• Early evaluation of persistent or recurrent ulcer symptoms, especially if ulcers occur distal to the duodenum.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Perforated ulcer – Sudden severe abdominal pain, peritonitis; requires emergency surgery.
• Upper gastrointestinal bleeding – Melena, hematemesis; may need endoscopic hemostasis or transfusion.
• Strictures – Healing scar tissue can narrow the duodenum or pylorus, causing obstruction.
• Malabsorption & osteoporosis – Chronic acid suppression interferes with calcium, iron, and vitamin B12 absorption.
• Metastatic gastrinoma – Liver or lymph‑node spread occurs in ~30 % of cases; reduces long‑term survival.
• NEUROENDOCRINE tumor syndrome complications – In MEN‑1, concurrent hyperparathyroidism or pituitary adenomas may develop.

When to Seek Emergency Care

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org
2. CDC. Pancreatic Cancer Statistics. https://www.cdc.gov
3. Capella C, et al. Multiple endocrine neoplasia type 1 (MEN‑1). Nat Rev Endocrinol. 2020;16:264‑277. PMCID: PMC3327334
4. American College of Gastroenterology. Diagnosis of Zollinger‑Ellison syndrome. Gastroenterology. 2021;160(2):720‑731. Link
5. Cleveland Clinic. Zollinger‑Ellison syndrome treatment overview. https://my.clevelandclinic.org

```